Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315).
A three-drug combination shows promise against a rare, aggressive cancer type that previously had few treatment options available.
This Phase 2 trial evaluated cabozantinib combined with dual checkpoint inhibition (nivolumab + ipilimumab) in poorly differentiated neuroendocrine carcinomas, providing clinical evidence for a novel triple combination in a tumor type with limited treatment options. Efficacy and safety data from the ETCTN10315 trial advance the treatment landscape for this rare, aggressive cancer.
What the study was
- Study design
- Phase 2 clinical trial
- Population
- Poorly differentiated neuroendocrine carcinoma patients (ETCTN10315 multicenter trial)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- The Oncologist
Why it surfaced
Phase 2 data for triple combination (cabozantinib + dual checkpoint inhibition) in poorly differentiated NEC fills an important clinical gap for a rare, treatment-refractory cancer.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.